Lineage Cell Therapeutics (LCTX) EBIT Margin (2010 - 2026)
Lineage Cell Therapeutics' (LCTX) quarterly EBIT Margin came in at 440.17% in Q1 2026, down 708.0% year-on-year from 72.4% in Q1 2025, and down 344.21% quarter-over-quarter from 99.09% in Q4 2025.
Lineage Cell Therapeutics (LCTX) EBIT Margin (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' EBIT Margin history runs 17 years deep, the most recent figure standing at 440.17% for Q1 2026.
- On a quarterly basis, EBIT Margin fell 708.0% year-over-year to 440.17% in Q1 2026; TTM through Mar 2026 was 255.14%, a 3204.0% decrease from a year earlier, with the FY2025 full-year figure at 251.57%, down 2547.0% from the prior year.
- EBIT Margin declined to 440.17% in Q1 2026 per LCTX's latest filing, from 99.09% in the prior quarter.
- Across five years, EBIT Margin topped out at 92.99% in Q2 2022 and bottomed at 715.37% in Q2 2025.
- The 5-year median for EBIT Margin is 278.37% (2023), against an average of 291.9%.
- Across the five-year window, EBIT Margin soared 168094 bps in 2022 and sank 36297 bps in 2023, its largest moves.
- Year by year, EBIT Margin stood at 346.68% in 2022, then increased by 12 bps to 304.69% in 2023, then soared by 42 bps to 178.17% in 2024, then jumped by 44 bps to 99.09% in 2025, then sank by 344 bps to 440.17% in 2026.
- Per Business Quant, the three latest LCTX EBIT Margin figures stand at 440.17% (Q1 2026), 99.09% (Q4 2025), and 102.85% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 267.08 Mn | 203.18 Mn | 1.73 Mn | -440.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -440.17% |
| Dec 31, 2025 | -99.09% |
| Sep 30, 2025 | -102.85% |
| Jun 30, 2025 | -715.37% |
| Mar 31, 2025 | -433.09% |
| Dec 31, 2024 | -178.17% |
| Sep 30, 2024 | -101.61% |
| Jun 30, 2024 | -416.69% |
| Mar 31, 2024 | -461.29% |
| Dec 31, 2023 | -304.69% |
| Sep 30, 2023 | -538.12% |
| Jun 30, 2023 | -155.78% |
| Mar 31, 2023 | -278.37% |
| Dec 31, 2022 | -346.68% |
| Sep 30, 2022 | -175.15% |
| Jun 30, 2022 | -92.99% |
| Mar 31, 2022 | -122.13% |
| Dec 31, 2021 | -56.48% |
| Sep 30, 2021 | -301.45% |
| Jun 30, 2021 | -1,382.81% |